|
|
|
|
|
1
|
Competitor Analysis: TGF-R Agonists and Antagonists |
Nov 2009 |
$297.00 |
|
The present Competitive Intelligence Report about TGF-R agonists and antagonists provides a competitor evaluation in the field of transforming growth factor receptor (TGF-R) or TGF targeting molecules for tissue healing or treatment of cancer and
more...
Published by: La Merie S.L.
|
|
|
2
|
Competitor Analysis: Thrombopoiesis-Stimulating Agents (TPO) |
Nov 2009 |
$223.00 |
|
The Competitive Intelligence Report Thrombopoiesis Stimulating Agents (TPO, IL-11) as of November 2009 provides information on thrombopoiesis stimulating agents targeting the thrombopoietin, interleukin-11 or other receptors on the market and in development.
The product portfolio
more...
Published by: La Merie S.L.
| Search inside this report |
|
|
3
|
Competitor Analysis: FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART) |
Nov 2009 |
$297.00 |
|
The Competitive Intelligence Report FSH, hCG and LH: Therapeutic Proteins for Assisted Reproductive Technology (ART) as of November 2009 provides a competitor analysis in the development pipeline of novel recombinant, transgenic and oral FSH, hCG
more...
Published by: La Merie S.L.
| Search inside this report |
|
|
4
|
Competitor Analysis: FGF-R Agonists and Antagonists |
Nov 2009 |
$445.00 |
|
The present Competitive Intelligence Report about FGF-R agonists and antagonists provides a competitor evaluation in the field of fibroblast growth factor receptor (FGF-R) or PDGF targeting molecules for wound healing, cardiac tissue repair, bone formation
more...
Published by: La Merie S.L.
|
|
|
5
|
Competitor Analysis: Coagulation Factors |
Oct 2009 |
$2,115.00 |
|
The present Competitive Intelligence Report about Coagulation Factors provides a competitor evaluation in the field of plasma-derived and recombinant coagulation factors for topical or systemic administration to treat hereditary or acquired coagulation disorders as of
more...
Published by: La Merie S.L.
|
|
|
6
|
Competitor Analysis: PDGF-R Agonists and Antagonists |
Oct 2009 |
$1,269.00 |
|
The present Competitive Intelligence Report about PDGF-R agonists and antagonists provides a competitor evaluation in the field of platelet derived growth factor receptor (PDGF-R) or PDGF targeting molecules for wound healing, bone formation or treatment
more...
Published by: La Merie S.L.
|
|
|
7
|
Competitor Analysis: EGF-R Agonists and Antagonists |
Sep 2009 |
$1,692.00 |
|
The present Competitive Intelligence Report about EGF-R agonists and antagonists provides a competitor evaluation in the field of epidermal growth factor receptor (EGF-R; ErbB1) targeting molecules for wound healing or treatment of cancer as of
more...
Published by: La Merie S.L.
|
|
|
8
|
Competitor Analysis: Her2 Receptor Antagonists |
Sep 2009 |
$1,056.00 |
|
The present Competitive Intelligence Report about Her2 receptor antagonists provides a competitor evaluation in the field of Her2 (ErbB2) receptor targeting molecules for treatment of cancer as of September 2009.
Targeted treatment of
more...
Published by: La Merie S.L.
|
|
|
9
|
Competitor Analysis: VEGF and VEGF-R Agonists and Antagonists |
Sep 2009 |
$2,538.00 |
|
The present Competitive Intelligence Report about VEGF and VEGF-R agonists and antagonists provides a competitor evaluation in the field of VEGF and its receptor targeting molecules for treatment of cancer, AMD and for neuroprotection as
more...
Published by: La Merie S.L.
|
|
|
10
|
Coagulation Factors 2009: Target Pipeline and Corporate Benchmark Analysis |
Aug 2009 |
$3,454.00 |
|
The “Coagulation Factors 2009: Target Pipeline and Corporate Benchmark Analysis” report is the most complete and up-to-date evaluation and assessment of the recombinant and plasma-derived coagulation factor pipelines. The authors analyze and assess the target
more...
Published by: La Merie S.L.
| Search inside this report |
|
|
11
|
Competitor Analysis: CHK and KSP/Eg5 Inhibitors |
Aug 2009 |
$750.00 |
|
The present Competitive Intelligence Report about checkpoint kinase (CHK) and kinesin spindle protein (KSP) or Eg5 inhibitors provides a competitor evaluation in the field of novel molecular entities inhibiting CHK or KS/Eg5 for treatment of
more...
Published by: La Merie S.L.
|
|
|
12
|
Competitor Analysis: Targeted Therapy of Hepatitis C |
Aug 2009 |
$2,115.00 |
|
The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2009.
Most hepatitis C
more...
Published by: La Merie S.L.
|
|
|
13
|
Competitor Analysis: IGF-1R Antagonists |
Jul 2009 |
$1,050.00 |
|
The present Competitive Intelligence Report about IGF-1R Antagonists provides a competitor evaluation in the field of novel molecular entities directed against the insulin-like growth factor-1 receptor (IGF-1R) or its ligands IGF-1 and IGF-2 for treatment
more...
Published by: La Merie S.L.
|
|
|
14
|
Competitor Analysis: Bcr-Abl and Src Kinase Inhibitors |
Jul 2009 |
$840.00 |
|
The present Competitive Intelligence Report about Bcr-Abl and Src Kinase Inhibitors provides a competitor evaluation in the field of novel molecular entities inhibiting Bcr-Abl and/or Src kinase for treatment of cancer as of July 2009.
more...
Published by: La Merie S.L.
|
|
|
15
|
Competitor Analysis: PI3K-AKT-mTOR Inhibitors |
Jul 2009 |
$2,115.00 |
|
The present Competitive Intelligence Report about PI3K-AKT-mTOR Inhibitors provides a competitor evaluation in the field of novel molecular entities inhibiting members of the phosphatidyl-inositol-3 kinase (PI3K) / Akt / mammalian target of rapamycin (mTOR) pathway
more...
Published by: La Merie S.L.
|
|
|
16
|
Competitor Analysis HDAC Inhibitors |
Jul 2009 |
$1,680.00 |
|
The present Competitive Intelligence Report about HDAC Inhibitors provides a competitor evaluation in the field of novel molecular entities inhibiting histone deacetylase for treatment of cancer and other diseases as of July 2009. Purchase of
more...
Published by: La Merie S.L.
|
|
|
17
|
Competitor Analysis: Immunotoxins |
Jul 2009 |
$210.00 |
|
The present Competitive Intelligence Report about Immunotoxins provides a competitor evaluation in the field of tumor targeted toxins by means of antibodies or proteins for treatment of cancer as of July 2009.
Immunotoxin
more...
Published by: La Merie S.L.
| Search inside this report |
|
|
18
|
Competitor Analysis: MEK Inhibitors |
Jun 2009 |
$210.00 |
|
The present Competitive Intelligence Report about MEK Inhibitors provides a competitor evaluation in the field of synthetic molecules targeting MEK pathway for treatment of cancer as of June 2009.
The mitogen activated protein
more...
Published by: La Merie S.L.
| Search inside this report |
|
|
19
|
Competitor Analysis: Aurora Kinase Inhibitors |
Jun 2009 |
$250.00 |
|
The present Competitive Intelligence Report about Aurora Kinase Inhibitors provides a competitor evaluation in the field of synthetic molecules targeting aurora kinase for treatment of cancer as of June 2009.
Mitosis, a central
more...
Published by: La Merie S.L.
| Search inside this report |
|
|
20
|
Competitor Analysis: Immunocytokines |
Jun 2009 |
$212.66 |
|
The present Competitive Intelligence Report about Immunocytokines provides a competitor evaluation in the field of tumor targeted cytokines by means of antibodies, proteins, peptides and other carriers for treatment of cancer as of June 2009.
more...
Published by: La Merie S.L.
| Search inside this report |
|
|
21
|
Competitor Analysis: Novel Mitotic Kinase Inhibitors |
Jun 2009 |
$500.00 |
|
The present Competitive Intelligence Report about Novel Mitotic Kinase Inhibitors provides a competitor evaluation in the field of synthetic molecules targeting polo-like kinase 1 (Plk-1), cyclin-dependent kinase (CDK) or aurora kinase for treatment of cancer
more...
Published by: La Merie S.L.
| Search inside this report |
|
|
22
|
Competitor Analysis: Antibody-Drug Conjugates (ADC) |
Jun 2009 |
$354.43 |
|
The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated with a drug payload for treatment of cancer as of June 2009.
more...
Published by: La Merie S.L.
| Search inside this report |
|
|
23
|
Competitor Analysis: NGF Agonists & Antagonists |
May 2009 |
$140.00 |
|
The present Competitive Intelligence Report about Nerve Growth Factor (NGF) Agonists & Antagonists provides a competitor evaluation in the field of investigational antibodies, small molecules and gene therapeutic approaches for treatment of chronic pain or
more...
Published by: La Merie S.L.
| Search inside this report |
|
|
24
|
Competitor Analysis: Ras-Raf-MEK-ERK Inhibitors |
May 2009 |
$500.00 |
|
The present Competitive Intelligence Report about Ras-Raf-MEK-ERK Inhibitors provides a competitor evaluation in the field of synthetic and biologic molecules targeting Ras-Raf-MEK-ERK pathway for treatment of cancer as of May 2009.
The mitogen
more...
Published by: La Merie S.L.
| Search inside this report |
|
|
25
|
Competitor Analysis: Hypoxia-Inducible Factor (HIF) |
Apr 2009 |
$140.00 |
|
The present Competitive Intelligence Report about Hypoxia-Inducible Factor (HIF) provides a competitor evaluation in the field of investigational small molecules and RNA inhibiting HIF-1alpha or HIF-2 for treatment of cancer or acting as HIF agonists
more...
Published by: La Merie S.L.
| Search inside this report |
|
|
|
|
|
0 items
